Live
FierceBiotechNIH grant cuts hit women, early-career scientists the hardest: analysisFierceBiotechMRI providers keep eye on rising helium prices amid war in IranEndpoints NewsNovartis to invest $480M in China following AstraZeneca and Lilly pledgesEndpoints NewsFDA posts photos of Indian drugmaking facility cited in warning letterIlluminaIllumina : CSR Report (2025 illumina france gender pay gap english) - marketscreener.comRoche MediaMinistry of Health and Population and Roche Diagnostics sign MoU to advance digital pathology in Egypt - Intelligent CIOBioPharma DiveApogee strengthens case for longer-lasting eczema drugBioPharma DivePfizer, Valneva to seek approval of Lyme disease vaccine despite mixed study resultsAgilentAgilent, Axion Nix Patent Trial, Pause Cases as They Near Deal - Bloomberg Law NewsFierceBiotechApogee eczema data drive hype to new peak as threat to Lilly and Sanofi becomes clearFierceBiotechSanofi returns to T-cell engager territory with $1.2B pact for phase 1-stage trispecificFierceBiotechFDA solicits feedback on controversial national priority voucher review pathway
Agilent Mar 23, 2026

Agilent, Axion Nix Patent Trial, Pause Cases as They Near Deal - Bloomberg Law News

Agilent, Axion Nix Patent Trial, Pause Cases as They Near Deal - Bloomberg Law News

Original
Body unavailable. Use the original source.

Directory

59 All